Literature DB >> 30900429

The Author Reply: Genetic Data Are a Prerequisite for Interpreting Clinical and Muscle Biopsy Findings in MELAS.

Young Mock Lee1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 30900429      PMCID: PMC6433570          DOI: 10.3349/ymj.2019.60.4.401

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


× No keyword cloud information.
We would like to thank Dr. Finsterer for raising a number of important points on our paper, and agree that there were some shortcomings in our current study. Muscle biopsy has been included in the routine analysis workup for mitochondrial disease patients if their diagnosis could not be confirmed by genetic testing. However, the usefulness of muscle biopsy, in terms of an initial diagnostic evaluation, remains unknown. In the current study, we aimed to evaluate whether muscle biopsy is useful in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients as an initial diagnostic evaluation, and our results strongly suggested that muscle biopsy should be considered in clinically suspected MELAS patients with weakness, if not confirmed by genetic testing. Unfortunately, there has been no previous study on the usefulness of muscle biopsy as an initial diagnostic evaluation. It is well-known that mitochondrial diseases are a heterogeneous group of disorders. Generally, the classification of a syndrome or a disease relies on accurate clinical, biochemical, and genetic information, and it may be based on either genotype or phenotype. But in cases of mitochondrial diseases, it is difficult to draw a clear line due to their heterogeneity.1 This study was retrospective in nature, which led to several limitations. Due to its rarity, the size of our study population was small, which could have given the impression that subjects were not enough for making generalized interpretations.23 So instead, we applied strict criteria on the patient group. Medical records of patients who were diagnosed with MELAS were reviewed based on the diagnostic criteria of Yatsuga, et al.,4 and patients without mtDNA mutation were excluded from the analysis.5 We do agree and understand Dr. Finsterer's view on the points that were raised. The study would have been more meaningful if prospective investigations could have been carried out. However, we would like to stress that a retrospective study also delivers a meaningful result despite its limitations. Again, we sincerely appreciate Dr. Finsterer's inspiring and insightful comments on this study.
  5 in total

1.  MELAS: a nationwide prospective cohort study of 96 patients in Japan.

Authors:  Shuichi Yatsuga; Nataliya Povalko; Junko Nishioka; Koju Katayama; Noriko Kakimoto; Toyojiro Matsuishi; Tatsuyuki Kakuma; Yasutoshi Koga
Journal:  Biochim Biophys Acta       Date:  2011-04-02

2.  Cause of Death in Children With Mitochondrial Diseases.

Authors:  Soyong Eom; Ha Neul Lee; Sunho Lee; Hoon-Chul Kang; Joon Soo Lee; Heung Dong Kim; Young-Mock Lee
Journal:  Pediatr Neurol       Date:  2016-10-13       Impact factor: 3.372

3.  Clinical Perspectives of Mitochondrial Disorders.

Authors:  Josef Finsterer
Journal:  Pediatr Endocrinol Rev       Date:  2018-09

4.  Ophthalmoplegia in Mitochondrial Disease.

Authors:  Sang Jun Lee; Ji Hoon Na; Jinu Han; Young Mock Lee
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

5.  Correlation of Serum Biomarkers and Magnetic Resonance Spectroscopy in Monitoring Disease Progression in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Due to mtDNA A3243G Mutation.

Authors:  Ha Neul Lee; Choon-Sik Yoon; Young-Mock Lee
Journal:  Front Neurol       Date:  2018-07-27       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.